R&D JP Morgan Week 2025 - Day 3 pharmaphorum's JPM Week live blog finishes strong with panels on AI, funding, and a conference wrap-up.
R&D JP Morgan Week 2025 - Day 2 On day 2 of pharmaphorum's JPM Week blog, we'll hear from leaders from the President of Novartis, a stacked industry panel on AI, and Dr Jill Biden.
News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
R&D JP Morgan Week 2025 - Day 1 On day 1 of JPM Week, join pharmaphorum as we hear about pharma's dealmaking plans and the changing pharma landscape.
News J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
